Semaglutide outperformed 7 diabetes medications in reducing risk of Alzheimer's disease, according to a study of over 1 ...

GLP-1 drugs like Wegovy (NVO) might help with weight loss, but they aren’t leading to lower health care costs yet, according ...

Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known ...

The U.K. government issued a new warning aimed at the misuse of GLP-1 therapies by those who don’t qualify for the meds but are instead using them for quick-fix weight loss.

A new study found a link between NovoNordisk’s blockbuster drug Ozempic and a reduced risk of Alzheimer’s disease. 23andMe, ...

Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of Alzheimer’s disease for certain groups, a new study finds.

Semaglutide, found in Novo Nordisk's Ozempic, may reduce Alzheimer's risk in type 2 diabetes patients, per new research. FDA ...

Semaglutide, the active ingredient found in Ozempic and Wegovy, may reduce the risk of Alzheimer’s disease, a new study published Thursday morning finds.

A new study is adding to evidence that GLP-1 drugs such as Novo Nordisk's semaglutide and Eli Lilly's tirzepatide could also ...

In the same week that Eli Lilly filed three lawsuits against online vendors and wellness spas making compounded versions of ...

As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial headwinds to pay for prescription drugs for weight loss. Semaglutide, the generic ...